![]() |
F-36P細(xì)胞
- 品牌:ACCEGEN
- 產(chǎn)地:美國
- 型號:1 vial
- 貨號:ABC-TC515S
- 發(fā)布日期: 2022-09-05
- 更新日期: 2024-08-12
產(chǎn)品詳請
產(chǎn)地 | 美國 |
保存條件 | 低溫保存 |
品牌 | ACCEGEN |
貨號 | ABC-TC515S |
用途 | For research use only |
組織來源 | 詳詢 |
細(xì)胞形態(tài) | 詳詢 |
是否是腫瘤細(xì)胞 | |
CAS編號 | |
保質(zhì)期 | 詳詢 |
器官來源 | 詳詢 |
免疫類型 | 詳詢 |
品系 | 詳詢 |
生長狀態(tài) | 詳詢 |
物種來源 | Human |
包裝規(guī)格 | 1 vial |
純度 | 詳詢% |
是否進(jìn)口 | 是 |
Product Name |
F-36P |
|||
Cat.No |
ABC-TC515S |
Species |
Human |
|
Size/Quantity |
1 vial |
|||
Shipping Info |
Dry Ice |
Storage |
Liquid Nitrogen |
|
Description |
Established at diagnosis of a 68-year-old male with acute myeloid leukemia (AML M6) secondary to myelodysplastic syndrome (MDS, subtype refractory anemia with excess of blasts, RAEB) in 1989; Cells were described to be proliferatively responsive to GM-CSF and IL-3. Cells have been shown to synthesize haemoglobin when GM-CSF or IL-3 is substituted by erythropoietin (Epo). They have been reported to be positive for leukocyte common antigen (CD45) and some multilineage markers such as CD13, CD33 and CD34, but are negative for T- and B-cell antigens and mature myelomonocytic antigens. Due to their reaction with some monoclonal antibodies recognising erythroid and platelet glycoproteins it has been suggested that F-36P has a multilineage phenotype.
于1989年診斷1例68歲男性急性髓系白血病(AML M6)繼發(fā)于骨髓增生異常綜合征(MDS,亞型難治性貧血,母細(xì)胞過多,RAEB);細(xì)胞被描述為對GM-CSF和IL-3有增殖反應(yīng)。細(xì)胞合成血紅蛋白時(shí)GM-CSF或IL-3被紅細(xì)胞生成素(Epo)取代。據(jù)報(bào)道,它們對白細(xì)胞共同抗原(CD45)和一些多系標(biāo)志物如CD13、CD33和CD34呈陽性反應(yīng),但對T、b細(xì)胞抗原和成熟的髓單核細(xì)胞抗原呈陰性反應(yīng)。由于其與一些識別紅細(xì)胞和血小板糖蛋白的單克隆抗體的反應(yīng),已被認(rèn)為F-36P具有多系表型。
|
|||
Growth Properties |
Round to polymorphic cells, Lymphocyte-like |
|||
Recommended Medium And Supplement |
RPMI-1640 Medium + 20% FBS + 10 ng/mL GM-CSF or 5 ng/mL rh IL-3 |
|||
Application |
For research use only |
|||
Product Type |
Human Leukemia Cell Lines |
|||
Product Image |
![]() |
相關(guān)產(chǎn)品: